Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sicurezza e tollerabilità di singole dosi ascendenti per via endovenosa (IV) di REGN5381 in pazienti adulti con insufficienza cardiaca con pressione capillare polmonare elevata

3 settembre 2026 aggiornato da: Regeneron Pharmaceuticals

Uno studio randomizzato, in doppio cieco, controllato con placebo, multicentrico per valutare la sicurezza, la tollerabilità, la farmacocinetica e la farmacodinamica di singole dosi ascendenti di REGN5381, un agonista NPR1, in pazienti con insufficienza cardiaca con pressione capillare polmonare elevata

This study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication for right heart catheterization (RHC). The aim of the study is to evaluate the safety and tolerability of the study drug.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Note: Group A has stopped enrolling and Group B will not enroll participants

Tipo di studio

Interventistico

Iscrizione (Effettivo)

59

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Chisinau, Moldavia, 2025
        • ARENSIA Exploratory Medicine at the Republican Clinical Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

  1. Body mass index (BMI) between 18 and 35 kg/m^2, inclusive, rounded to the nearest whole number
  2. Ambulatory participants with New York Heart Association (NYHA) class II/III heart failure and at least 1 sign and/or symptom of congestion (eg, dyspnea on exertion, worsening edema, orthopnea, etc.)
  3. Left ventricular ejection fraction (LVEF) ≥20 % and <50% on echocardiogram (ie, HFrEF participants) within 90 days prior to randomization (only for HFrEF participants in Group A and Group B).
  4. Participants who, in the opinion of the investigator, require a right heart catheterization (not applicable for HFrEF patients not taking sacubitril/valsartan [Group A]).
  5. Left ventricular ejection fraction (LVEF) ≥50% on echocardiogram (ie, HFpEF participants) within 90 days prior to randomization (only for HFpEF participants in Group C)
  6. NT-proBNP >1000 pg/mL or Brain Natriuretic Peptide (active form) (BNP) >300 pg/mL as described in the protocol within 30 days prior to randomization measured by the local laboratory (only for HFrEF participants [Group A and Group B]).
  7. Pulmonary capillary wedge pressure (PCWP) ≥15 mmHg and right artrial pressure (RAP) >5 mmHg on right heart catheterization (RHC) the morning of anticipated study drug dose administration (not applicable for HFrEF participants not taking sacubitril/valsartan [Group A] as described in the protocol).
  8. Systolic blood pressure (SBP) ≥110 mmHg at the screening visit and on day -1
  9. Hematocrit >30% at the screening visit and day -1

Key Exclusion Criteria:

  1. Currently taking IV vasodilators and/or inotropes
  2. Taking sacubitril/valsartan (only for HFrEF and HFpEF participants not taking sacubitril/valsartan [Group A and Group C, respectively])
  3. Taking a phosphodiesterase (PDE) inhibitor (eg, sildenafil), or a soluble guanylate cyclase stimulator (SGCS; ie, vericiguat) within 2 weeks of the screening visit or planning on taking valsartan/sacubitril, a PDE inhibitor, or a SGCS at any point during the study
  4. More than moderate valvular regurgitation/stenosis (ie, moderate-to-severe or severe) on echocardiogram within 90 days prior to randomization
  5. Known infiltrative or hypertrophic cardiomyopathy
  6. Acute coronary syndrome within prior 6 months of randomization
  7. History of cardiac arrest
  8. Cardiac surgery within 3 months of randomization
  9. Pacemaker or defibrillator placement within prior 30 days of randomization
  10. Severe chronic obstructive pulmonary disease (COPD) (defined as Forced Expiratory Volume in 1st second [FEV1] <50% of predicted or Global Initiative for Chronic Obstructive Lung Disease [GOLD] 3 or 4)
  11. Pulmonary arterial hypertension (World Health Organization [WHO] Group 1) and any medical history at any time of more than moderate pulmonary hypertension (ie, moderate-to-severe, or severe pulmonary hypertension, as described in the protocol
  12. Congenital heart disease (repaired or unrepaired)
  13. Inability to lie flat for cardiac catheterization

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group A

Randomized 1:1; limited to participants with heart failure with reduced ejection fraction (HFrEF) not taking sacubitril/valsartan

Single dose administered via IV infusion

Single dose administered via IV infusion

Sperimentale: Group B

Randomized 1:1; limited to participants with HFrEF taking sacubitril/valsartan

Single dose administered via IV infusion

Single dose administered via IV infusion

Sperimentale: Group C

Randomized 1:1; limited to participants with heart failure with preserved ejection fraction (HFpEF) not taking sacubitril/valsartan

Single dose administered via IV infusion

Single dose administered via IV infusion

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Lasso di tempo: From first dose (Day 1) up to end of study (Day 126)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as those adverse events with either initial onset after study drug dose or that represented an exacerbation of a pre-existing condition after the study drug dose.

From first dose (Day 1) up to end of study (Day 126)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP)
Lasso di tempo: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)

PCWP was collected during the right heart catheterization on Day 1.

Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
Change From Baseline in Central Venous Pressure (CVP)
Lasso di tempo: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)

CVP was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CVP was not captured.

Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Change From Baseline in Invasive Cardiac Output (CO)
Lasso di tempo: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)

CO was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CO was not captured.

Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Change From Baseline in Systemic Vascular Resistance (SVR)
Lasso di tempo: Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)

SVR was derived as follows: [(Mean Arterial Pressure-Central Venous Pressure)*80]/ Invasive Cardiac Output. For the Group A: 10 mg cohort, the site's bedside monitor was not compatible with the invasive hemodynamic measurement device. As a result, CVP was not captured, and SVR could not be calculated due to the missing CVP data.

Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)
Lasso di tempo: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)

mPAP was collected during the right heart catheterization on day 1.

Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Change From Baseline in Pulmonary Vascular Resistance (PVR)
Lasso di tempo: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)

Pulmonary Vascular Resistance was derived as follows: [(Mean Pulmonary Artery Pressure-Pulmonary Capillary Wedge Pressure)*80]/ Invasive Cardiac Output.

Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
Change From Baseline in Systolic Blood Pressure (SBP)
Lasso di tempo: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing right heart catheterization (RHC).

Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Change From Baseline in Diastolic Blood Pressure (DBP)
Lasso di tempo: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.

Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Change From Baseline in Mean Arterial Pressure (MAP)
Lasso di tempo: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

MAP was derived as follows: (1/3*SBP + 2/3*DBP).

Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Change From Baseline in Pulse Rate (PR)
Lasso di tempo: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

For participants enrolled in Group A cohorts, pulse rate was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.

Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Fold Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
Lasso di tempo: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) *100. Fold Change from Baseline is the ratio of Post-Baseline to Baseline, and it is assumed to follow a lognormal distribution. Per the study design, only some participants had a Day 4/Day 5 visit. Therefore, NT-proBNP data were not collected at this time point for all participants.

Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Peak Concentration (Cmax) of REGN5381 in Serum
Lasso di tempo: Up to Day 126
Up to Day 126
Area Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum
Lasso di tempo: Up to Day 126
Up to Day 126
Number of Participants With Anti-drug Antibodies (ADA)
Lasso di tempo: Baseline up to Day 126

The ADA status of each participant was classified as one of the following:

  • Negative - If all samples were found to be negative in the ADA assay
  • Pre-existing immunoreactivity - If the baseline sample was positive and all post baseline ADA titers were reported as less than 9-fold the baseline titer value
  • Treatment-Boosted Response
  • Treatment-Emergent Response
Baseline up to Day 126

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Trial Management, Regeneron Pharmaceuticals

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 giugno 2022

Completamento primario (Effettivo)

2 giugno 2025

Completamento dello studio (Effettivo)

2 giugno 2025

Date di iscrizione allo studio

Primo inviato

25 aprile 2022

Primo inviato che soddisfa i criteri di controllo qualità

25 aprile 2022

Primo Inserito (Effettivo)

29 aprile 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • R5381-HF-2159
  • 2021-006337-19 (Numero EudraCT)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 2023-506674-13-00 (Ctis)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Periodo di condivisione IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Criteri di accesso alla condivisione IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .